Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials
The objective of this meta-analysis is to assess the safety and immunogenicity of maternal pertussis vaccination based on randomized clinical trials. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Internet, and Wan Fang Database were searched from inception up to the 8th...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Tropical Medicine |
| Online Access: | http://dx.doi.org/10.1155/2022/4857872 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567140833558528 |
|---|---|
| author | Aidibai Simayi Liguo Zhu Hui Jin |
| author_facet | Aidibai Simayi Liguo Zhu Hui Jin |
| author_sort | Aidibai Simayi |
| collection | DOAJ |
| description | The objective of this meta-analysis is to assess the safety and immunogenicity of maternal pertussis vaccination based on randomized clinical trials. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Internet, and Wan Fang Database were searched from inception up to the 8th of October 2021, using a protocol registered on PROSPERO with no. 42021287717, and a meta-analysis was conducted. We measured pooled geometric mean concentrations (GMCs) for IgG antibodies against pertussis and the incidence of serious adverse events (SAEs). We identified a total of 522 publications, and after a strict screening, we found that 6 RCTs were eligible for our meta-analysis. GMCs were determined with a standardized mean difference (SMD), and the pooled SMD of anti-PT, anti-FHA, and anti-PRN IgG from cord blood were 0.91 (95% CI: 0.58, 1.24), 1.03 (95% CI: (0.70, 1.35)), and 1.55(95% CI: 1.22, 1.88), respectively. The pooled OR of SAEs of women and infants did not show a statistical difference; the pooled ORs were 1.26 (95% CI: 0.78, 2.05); P=0.35) and 0.61 (95% CI: 0.37, 1.01); p=0.053), respectively. Infants of immunized women have significantly higher transplacental antibodies for protection against pertussis disease during the first 2 months of life. |
| format | Article |
| id | doaj-art-f44840c5af3b448081c23d0fb7d5a23b |
| institution | Kabale University |
| issn | 1687-9694 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Tropical Medicine |
| spelling | doaj-art-f44840c5af3b448081c23d0fb7d5a23b2025-02-03T01:02:22ZengWileyJournal of Tropical Medicine1687-96942022-01-01202210.1155/2022/4857872Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical TrialsAidibai Simayi0Liguo Zhu1Hui Jin2Department of Epidemiology and Health StatisticsDepartment of Acute Infectious Disease Control and PreventionDepartment of Epidemiology and Health StatisticsThe objective of this meta-analysis is to assess the safety and immunogenicity of maternal pertussis vaccination based on randomized clinical trials. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Internet, and Wan Fang Database were searched from inception up to the 8th of October 2021, using a protocol registered on PROSPERO with no. 42021287717, and a meta-analysis was conducted. We measured pooled geometric mean concentrations (GMCs) for IgG antibodies against pertussis and the incidence of serious adverse events (SAEs). We identified a total of 522 publications, and after a strict screening, we found that 6 RCTs were eligible for our meta-analysis. GMCs were determined with a standardized mean difference (SMD), and the pooled SMD of anti-PT, anti-FHA, and anti-PRN IgG from cord blood were 0.91 (95% CI: 0.58, 1.24), 1.03 (95% CI: (0.70, 1.35)), and 1.55(95% CI: 1.22, 1.88), respectively. The pooled OR of SAEs of women and infants did not show a statistical difference; the pooled ORs were 1.26 (95% CI: 0.78, 2.05); P=0.35) and 0.61 (95% CI: 0.37, 1.01); p=0.053), respectively. Infants of immunized women have significantly higher transplacental antibodies for protection against pertussis disease during the first 2 months of life.http://dx.doi.org/10.1155/2022/4857872 |
| spellingShingle | Aidibai Simayi Liguo Zhu Hui Jin Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials Journal of Tropical Medicine |
| title | Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials |
| title_full | Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials |
| title_fullStr | Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials |
| title_full_unstemmed | Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials |
| title_short | Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials |
| title_sort | safety and immunogenicity of pertussis vaccine immunization during pregnancy a meta analysis of randomized clinical trials |
| url | http://dx.doi.org/10.1155/2022/4857872 |
| work_keys_str_mv | AT aidibaisimayi safetyandimmunogenicityofpertussisvaccineimmunizationduringpregnancyametaanalysisofrandomizedclinicaltrials AT liguozhu safetyandimmunogenicityofpertussisvaccineimmunizationduringpregnancyametaanalysisofrandomizedclinicaltrials AT huijin safetyandimmunogenicityofpertussisvaccineimmunizationduringpregnancyametaanalysisofrandomizedclinicaltrials |